Hyperviscosity Retinopathy Due to Waldenström Macroglobulinemia: A Case Report and Literature Review

2021 ◽  
pp. 247412642098714
Author(s):  
Julia A. Watson ◽  
Daniel J. Olson ◽  
Alice Yang Zhang
Keyword(s):  
Case Report ◽  
Growth Factor ◽  
Fluorescein Angiography ◽  
Subretinal Fluid ◽  
Malignant Neoplasm ◽  
Fundus Photography ◽  
Oct Angiography ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
Endothelial Growth Factor

Purpose: This case report describes a case of hyperviscosity retinopathy secondary to the rare systemic hematologic malignant neoplasm Waldenström macroglobulinemia. Methods: Fundus photography, fluorescein angiography, optical coherence tomography (OCT), and OCT angiography were used as imaging modalities to characterize this pathology. Results: A 51-year-old man presented with hyperviscosity retinopathy and uniquely angiographically silent serous macular detachment. Over a 6-month period, he was treated with systemic and local therapies with little improvement in the hyperviscosity retinopathy, serous macular detachments, or visual acuity. Conclusions: Hyperviscosity retinopathy secondary to Waldenström macroglobulinemia presents a challenge to treating ophthalmologists given its rarity and the range of treatment responses described in the literature. Our patient’s lack of response to antivascular endothelial growth factor and normal findings in OCT angiography and fluorescein angiography suggested the mechanism of subretinal fluid accumulation was not vascular endothelial growth factor mediated. Visual prognosis was guarded.

scholarly journals Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

2014 ◽  
Vol 48 (2) ◽  
pp. 184-188 ◽  
Author(s):  
Robert Königsberg ◽  
Julia Maierhofer ◽  
Tanja Steininger ◽  
Gabriele Kienzer ◽  
Christian Dittrich
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Growth Factor ◽  
Antibody Therapy ◽  
Growth Factor Receptor ◽  
Over Expression ◽  
Single Target ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

AbstractBackground. The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor receptor 2 (Her2/neu) positive patients with breast cancer and over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF.Case report. The case of a Her2/neu positive patient with breast cancer who refused cytotoxic chemotherapy with its potential side effects as well as mastectomy is presented. Our patient has been receiving the combined double administration of bevacizumab and trastuzumab for more than 4 years.Conclusions. This case report shows that (a) the combined double administration of bevacizumab and trastuzumab was be clinically effective. (b) The combination of bevacizumab and trastuzumab is safe and non-toxic. (c) Bevacizumab and trastuzumab can be used as a long-term application

Obinutuzumab in the treatment of a patient with Waldenström macroglobulinemia and rituximab intolerance – a case report

2021 ◽  
Vol 27 (2) ◽  
pp. 160-165
Author(s):  
Zdeněk Adam ◽  
Marta Krejčí ◽  
Luděk Pour ◽  
Martin Štork ◽  
Viera Sandecká ◽  
...  
Keyword(s):  
Case Report ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia

scholarly journals A 5-Year-Old Case of Choroidal Neovascularization in Enhanced S-Cone Syndrome Treated with Ranibizumab

2018 ◽  
Vol 9 (3) ◽  
pp. 510-515 ◽  
Author(s):  
Federica Bertoli ◽  
Silvia Pignatto ◽  
Francesca Rizzetto ◽  
Paolo Lanzetta
Keyword(s):  
Case Report ◽  
Fluorescein Angiography ◽  
Choroidal Neovascularization ◽  
Subretinal Fluid ◽  
Intravitreal Ranibizumab ◽  
Genetic Studies ◽  
Visual Deterioration ◽  
Retinal Degenerations ◽  
The Right ◽  
Enhanced S Cone Syndrome

Introduction: We describe the youngest case of enhanced S-cone syndrome (ESCS) associated with choroidal neovascularization (CNV) successfully treated with intravitreal ranibizumab injections. Case Report: A 5-year-old boy presented with round-shaped fibrotic subretinal lesions in both eyes with surrounding subretinal fluid and progressive visual deterioration in the right eye. Fine foci of increased autofluorescence were observed along the arcades in both eyes. Fluorescein angiography revealed the presence of CNV in his right eye, and treatment with ranibizumab was initiated, with significant improvement in vision. Subsequent electroretinogram examination and genetic studies of the patient and his two younger siblings confirmed the diagnosis of ESCS. Conclusion: CNV has been reported to occur in different inherited retinal degenerations, including ESCS. Our experience confirms that treatment with ranibizumab in patients with CNV-complicated ESCS can be potentially vision-saving.

Agranulocytosis Associated with Waldenström Macroglobulinemia

2018 ◽  
Vol 140 (1) ◽  
pp. 42-45 ◽  
Author(s):  
Iuliana Vaxman ◽  
Daniel Shepshelovich ◽  
Lucille Hayman ◽  
Pia Raanani ◽  
Meir Lahav
Keyword(s):  
Case Report ◽  
Febrile Neutropenia ◽  
Medical History ◽  
Case Reports ◽  
Neutropenic Fever ◽  
Severe Neutropenia ◽  
Past Medical History ◽  
Waldenström Macroglobulinemia ◽  
Waldenstrom Macroglobulinemia ◽  
History Of

Currently, there are only 2 case reports of Waldenström macroglobulinemia (WM) associated with severe neutropenia. This is a case report of a woman with a past medical history of WM who presented with neutropenic fever. The patient’s febrile neutropenia resolved after RCD chemotherapy (cyclophosphamide 750 mg/m2, dexamethasone 20 mg, and rituximab 375 mg/m2). Fourteen days after administration, the neutrophil level had started to rise and normalized after 6 days. To the best of our knowledge, this is the 3rd reported case of agranulocytosis due to WM.

scholarly journals Symptomatic Hypoalbuminemia as an Indication for Treatment of Waldenström Macroglobulinemia: A Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Jeremy T. Larsen ◽  
Frederick D. Leonard
Keyword(s):  
Quality Of Life ◽  
Case Report ◽  
Primary Reason ◽  
Review Of The Literature ◽  
Gastrointestinal Involvement ◽  
Waldenström Macroglobulinemia ◽  
Symptomatic Disease ◽  
Waldenstrom Macroglobulinemia ◽  
Indication For Treatment

Hypoalbuminemia has been reported as common in patients with symptomatic Waldenström macroglobulinemia (WM), but it is not typically mentioned as a manifestation of the disease in review articles or articles discussing indications for treatment. We present the case of a patient with WM for whom symptomatic hypoalbuminemia was the primary reason for initiating treatment. Except in rare cases of WM with renal or gastrointestinal involvement, hypoalbuminemia is thought to be due to the effects of elevated levels of inflammation-associated cytokines, and it has been associated with greater likelihood of progression of asymptomatic to symptomatic disease, greater disease severity, and poorer prognosis. Hypoalbuminemia in WM may become symptomatic, and it may be a reason to initiate treatment if symptoms affect quality of life.

Sign in / Sign up

Export Citation Format

Share Document